Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de la vedotina de Enfortumab en personas con carcinoma quístico adenoides

28 de septiembre de 2026 actualizado por: Memorial Sloan Kettering Cancer Center

Prueba de fase II de la vedotina de Enfortumab en el carcinoma adenoide recurrente y/o metastásico

The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).

Descripción general del estudio

Estado

Reclutamiento

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

34

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Winston Wong, MD
  • Número de teléfono: 646-608-4245

Copia de seguridad de contactos de estudio

  • Nombre: Alan Ho, MD, PhD
  • Número de teléfono: 646-541-7062
  • Correo electrónico: hoa@mskcc.org

Ubicaciones de estudio

    • New Jersey
      • Basking Ridge, New Jersey, Estados Unidos, 07920
        • Reclutamiento
        • Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
        • Contacto:
          • Alan Ho, MD. PhD
          • Número de teléfono: 646-541-7062
      • Middletown, New Jersey, Estados Unidos, 07748
        • Reclutamiento
        • Memorial Sloan Kettering Monmouth (All Protocol Activities)
        • Contacto:
          • Alan Ho, MD, PhD
          • Número de teléfono: 646-541-7062
      • Montvale, New Jersey, Estados Unidos, 07645
        • Reclutamiento
        • Memorial Sloan Kettering Bergen (All Protocol Activities)
        • Contacto:
          • Alan Ho, MD, PhD
          • Número de teléfono: 646-541-7062
    • New York
      • Commack, New York, Estados Unidos, 11725
        • Reclutamiento
        • Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities)
        • Contacto:
          • Alan Ho, MD, PhD
          • Número de teléfono: 646-541-7062
      • East White Plains, New York, Estados Unidos, 10604
        • Reclutamiento
        • Memorial Sloan Kettering Westchester (All Protocol Activities)
        • Contacto:
          • Alan Ho, MD, PhD
          • Número de teléfono: 646-541-7062
      • New York, New York, Estados Unidos, 10065
        • Reclutamiento
        • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
        • Investigador principal:
          • Alan Ho, MD, PhD
        • Contacto:
          • Winston Wong, MD
          • Número de teléfono: 646-608-4245
        • Contacto:
          • Alan Ho, MD. PhD
          • Número de teléfono: 646-541-7062
      • Uniondale, New York, Estados Unidos, 11553
        • Reclutamiento
        • Memorial Sloan Kettering Nassau (All Protocol Activities)
        • Contacto:
          • Alan Ho, MD, PhD
          • Número de teléfono: 646-541-7062

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Patients must have pathologically or cytologically confirmed adenoid cystic carcinoma. Cancers arising from non-salivary gland primary sites are allowed.

  • Patients must have recurrent and/or metastatic disease not amenable to other curative intent therapy.

  • At least 4 weeks must have elapsed since the end of prior systemic treatment and/or 2 weeks since completion of radiotherapy with resolution of all treatment related toxicity to NCI CTCAE Version 5.0 grade <1 (or tolerable grade 2) or back to baseline (except for alopecia, lymphopenia, or hypothyroidism) prior to starting study drug treatment.

  • Patients must have RECIST V1.1 measurable disease, defined as at least one nonnodal lesion measuring ≥ 20 mm with conventional techniques or as ≥10mm with CT scan, MRI, or calipers by clinical exam in the longest dimension AND/OR a nodal lesion measuring ≥ 15 mm in the shortest dimension. Tumors in previously irradiated fields may be considered measurable if there is evidence of tumor progression after radiation treatment.

  • Patients must have documentation of a new or progressive lesion on radiologic imaging study performed within 6 months prior to study enrollment (progression of disease over any interval is allowed) and/or new/worsening disease related symptoms within 6 months prior to study enrollment. Note: This assessment will be performed by the treating investigator and evidence of progression by RECIST criteria is not required.

  • Age ≥ 18 years of age on the day of signing informed consent.

  • ECOG performance status 0 or 1 (or Karnofsky ≥ 70%).

  • Patients must have tissue from the primary tumor or metastases available for correlative studies. Either a paraffin block or at least 20 unstained slides are acceptable (paraffin block or at 30 unstained slides would be ideal). Patients without available tissue for submission may still be eligible if approved by the Principal Investigator. Additional tissue collection is not a requirement for this study.

  • Screening laboratory values must meet the following criteria:

    • Neutrophils ≥ 1500/μL
    • Platelets ≥ 100x10^3/μL
    • Hemoglobin > 9.0 g/dL (without packed red blood cell (pRBC) transfusion within the last 2 weeks)
    • AST and ALT ≤ 2.5 x ULN (if liver metastases are present, AST and ALT ≤ 5x ULN)
    • Total Bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels >1.5 x ULN (except participants with Gilbert Syndrome, who can have a total bilirubin < 3.0 mg/dL)
    • Serum creatinine ≤ 1.5 x ULN OR creatinine clearance (CrCl) ≥ 40 mL/min per the Cockcroft-Gault formula if creatinine is >1.5 x ULN
    • Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL
    • Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL
  • Participants must be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial specific procedure.

  • Male participants must agree to use adequate contraception and refrain from donating sperm from start of therapy through 4 months after last dose of trial treatment.

  • Female participants must agree not to donate ova starting at screening and throughout the study period, and for at least 3 weeks after the final dose of study drug.

  • A female participant is eligible to participate if 1) she is not pregnant (for women of child-bearing potential, a pregnancy test must be negative within 72 hours prior to initiation; if a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required) OR 2) she is not a woman of child bearing potential as defined by one of the following criteria:

    • Pre-menopausal with one of the following: documented hysterectomy, documented bilateral salpingectomy, documented bilateral oophorectomy
    • Postmenopausal females defined as no menses for 12 months without an alternative medical cause. However, in the absence of 12 months of amenorrhea, confirmation with two FSH measurements in the postmenopausal range is required.
  • A woman of childbearing potential must use highly effective contraception from the start of therapy through 2 months after the last dose of study medication.

Exclusion Criteria:

  • Untreated brain metastasis (subjects with treated brain metastases will be eligible, provided that they are radiographically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging [note that the repeat imaging should be performed during study screening], clinically stable and without requirement of steroid treatment for at least 14 days prior to the first dose of study treatment).
  • Prior malignancy if diagnosed and treated within 2 years of trial drug initiation. Patients may be included if they have completed therapy for a prior malignancy >2 years prior to drug initiation and are currently no evidence of disease (NED). Exception: Participants with non-melanoma skin cancer or carcinoma in situ (breast DCIS, or cervical CIS) that have undergone potentially curative therapy at any time are not excluded from trial participation.
  • Prior systemic anti-cancer therapy within 4 weeks of start of study treatment.
  • ≥ Grade 2 peripheral neuropathy per CTCAE v5.0 criteria.
  • Dry eyes, keratitis, keratopathy, and active conjunctivitis.
  • New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia associated with significant cardiovascular impairment within the past 6 months (baseline echocardiogram is not required unless clinically indicated).
  • Active infection, defined as any infection requiring systemic treatment
  • Subject is known to be positive for Human Immunodeficiency Virus (HIV) or active Hepatitis C Virus (HCV) or active hepatitis B (HBV) infection (positive viral load). Testing for HIV, HCV, or HBV prior to initiation of the study drug is not required. If patient's have a known history of treated HCV, then a viral load is required to confirm clearance of infection.
  • Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  • Renal failure requiring active hemo- or peritoneal dialysis.
  • Breast feeding is not allowed from the start of treatment through 3 weeks after the last dose of study drug.
  • Has a history or current evidence of any medical or other condition, therapy or laboratory abnormality which, in the opinion of the investigator, might confound the results of the study, or preclude participation in a clinical study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Enfortumab Vedotin

Participants are treated with enfortumab vedotin at the FDA-approved dose and schedule of intravenously on Days 1, 8 and 15 of a 28-day cycle.

intravenously on Days 1, 8 and 15 of a 28-day cycle-dose can be done up to +/-3 days after the scheduled day of administration

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
best overall response rate
Periodo de tiempo: 1 year

BOR; CR+PR by RECIST v1.1

1 year

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
progression-free survival (PFS)
Periodo de tiempo: 1 year

PFS will be estimated using Kaplan-Meier methodology, with time origin at the start of the treatment. Patients will be followed until progression of disease or death, whichever comes first.

1 year

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Colaboradores

Investigadores

  • Investigador principal: Alan Ho, MD, PhD, Memorial Sloan Kettering Cancer Center

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

31 de marzo de 2025

Finalización primaria (Estimado)

1 de marzo de 2027

Finalización del estudio (Estimado)

1 de marzo de 2027

Fechas de registro del estudio

Enviado por primera vez

18 de marzo de 2025

Primero enviado que cumplió con los criterios de control de calidad

18 de marzo de 2025

Publicado por primera vez (Actual)

24 de marzo de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

1 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

28 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • 24-215

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir